Edition:
United States

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

6.77USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,819
52-wk High
$27.77
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share
Wednesday, 14 Feb 2018 09:13am EST 

Feb 14 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.40 MILLION COMMON SHARES PRICED AT $6.00PER SHARE.  Full Article

Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 13 Feb 2018 05:44pm EST 

Feb 13 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS - INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $50 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
Thursday, 21 Dec 2017 04:01pm EST 

Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.  Full Article

Ra Pharmaceuticals posts Q3 loss of $0.68 per share
Thursday, 9 Nov 2017 04:22pm EST 

Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million​.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.  Full Article

Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
Wednesday, 1 Nov 2017 05:49pm EDT 

Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article

Ra Pharmaceuticals reports Q2 loss per share $0.56
Wednesday, 9 Aug 2017 04:18pm EDT 

Aug 10 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.56.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.Ra Pharmaceuticals Inc - ‍expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.Says no revenue recorded in three months ended June 30, 2017, compared to $3.0 million for same period in 2016.Q2 earnings per share view $-0.52, revenue view $833330.00 -- Thomson Reuters I/B/E/S.  Full Article

RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria
Monday, 31 Jul 2017 07:12am EDT 

July 31 (Reuters) - RA Pharmaceuticals Inc :RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria.RA Pharmaceuticals - ‍encouraged by initial phase 2 data in PNH patients, which showed near-complete inhibition of hemolysis, favorable safety profile​.  Full Article

Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495
Tuesday, 27 Jun 2017 07:00am EDT 

June 27 (Reuters) - Ra Pharmaceuticals Inc ::Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh.Ra Pharmaceuticals Inc - rapid declines in LDH and near-complete inhibition of hemolytic activity.Ra Pharmaceuticals Inc - review of initial safety and efficacy data enables opening of Eculizumab switch cohort.Ra Pharmaceuticals Inc - no safety or tolerability concerns identified; no injection site reactions in study.  Full Article

RA Pharmaceuticals Q1 loss per share $0.50
Thursday, 11 May 2017 04:20pm EDT 

May 11 (Reuters) - RA Pharmaceuticals Inc :RA Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.50.Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

RA Pharmaceuticals Q4 loss per share $0.74
Monday, 6 Mar 2017 05:00pm EST 

Ra Pharmaceuticals Inc : RA Pharmaceuticals reports fourth quarter and full year 2016 financial results and provides corporate update . Q4 loss per share $0.74 .Q4 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.  Full Article